Story perspectives

Teva Launches Biosimilars, Stock Soars Amid Growth Outlook

9/6/2025

Summary

Story summary

Teva Pharmaceutical Industries launched three biosimilars in the U.S. and plans five more by 2027.
The company’s stock rose 19.4% in the past month, fueled by strong sales of branded drugs like Austedo.
Generics sales remain flat due to competition and a divestment in Japan, but new launches may boost performance.
Analysts upgraded Teva's credit outlook, indicating confidence in its growth and efficiency.
Teva expects over $5 billion in branded product revenues by 2030, backed by a strong pipeline.

History

Historical Context

The Medicare Modernization Act of 2003 expanded prescription drug access in the U.S., significantly impacting the pharmaceutical landscape. Teva Pharmaceutical Industries, a leader in generics, has recently seen a 19.4% stock increase due to strong sales of branded drugs like Austedo and the launch of three biosimilars, aiming for over $5 billion in revenue by 2030.

1 of 2

Story summary

Teva Pharmaceutical Industries launched three biosimilars in the U.S. and plans five more by 2027.
The company’s stock rose 19.4% in the past month, fueled by strong sales of branded drugs like Austedo.
Generics sales remain flat due to competition and a divestment in Japan, but new launches may boost performance.
Analysts upgraded Teva's credit outlook, indicating confidence in its growth and efficiency.
Teva expects over $5 billion in branded product revenues by 2030, backed by a strong pipeline.

1 / 2